14087-98-0

Upstream product

• 20004-93-7 2-(4-chlorophenyl)-5-phenylvaleric acid 
• 20004-92-6 2-(4-chlorophenyl)-5-phenylvaleronitrile 
• 637-59-2 1-Bromo-3-phenylpropane 
• 106-39-8 bromochlorobenzene 
• 826-73-3 1-Benzosuberone 
• 140-53-4 p-chlorobenzyl cyanide 

Downstream Products

• 14088-09-6 6-(4-Chloro-phenyl)-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol 
• 118386-78-0 6-(4-Chloro-phenyl)-6,7,8,9-tetrahydro-benzocyclohepten-5-one oxime 
• 113843-01-9 3-(4-chlorophenyl)-1,2,3,4,5,6-hexahydro-1-benzazocin-2-one 
• 15249-25-9 (2-{4-[6-(4-Chloro-phenyl)-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl]-phenoxy}-ethyl)-diethyl-amine 
• 14087-83-3 4-[6-(4-Chloro-phenyl)-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl]-phenol 

Relevant academic research and scientific papers

BENZOCYCLOHEPTANE AND BENZOXEPINE DERIVATIVES

The present invention relates to a compound of formula (I), including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; provided that the compound is other than formula (B) or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.